Login to Your Account



Financings Roundup

Domo 'Regado': $51M to Fund REG1 Phase III in Thrombosis

By Randy Osborne
Staff Writer

Thursday, December 20, 2012

Regado Biosciences Inc.'s hefty Series E round on the brink of a Phase III with its anticoagulant REG1 is one of the larger private financings of the year, and the $51 million bets mainly on an approach to clotbusting that the company hopes will get around the bleeding risks that have beset others.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription